Differences between interferon-α and-β treatment for patients with chronic hepatitis C virus infection

Digestive Diseases and Sciences

Volumn 44, Issue 3, 1999, Pages 608-617

  Furusyo, Norihiro ^a   Hayashi, Jun ^a   Ohmiya, Misako ^a   Sawayama, Yasunori ^a   Kawakami, Yasunobu ^a   Ariyama, Iwao ^a   Kinukawa, Naoko ^a   Kashiwagi, Seizaburo ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Alanine aminotransferase; HCV RNA; Hepatitis C virus; Interferon ; Interferon ; Interleukin 6; Soluble interleukin 2 receptor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA INTERFERON; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS TYPING;

EID: 0032987514     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026625928117     Document Type: Article

References (32)

1. 1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThiel D, Tamburro C, Lefkowitch J, Albretch J, Meschievitz C, Ortego TJ, Gibas A, Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 321:1501-1506, 1989
2. 2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510, 1989
3. 3. Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, Kashiwagi S: A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 89:2151-2156, 1994
4. 4. Furusyo N, Hayashi J, Ueno K, Sawayama Y, Kawakami Y, Kishihara Y, Kashiwagi S: Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. Clin Ther 19:1352-1367, 1997
5. 5. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055, 1995
6. 6. Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, Sawayama Y, Kashiwagi S: Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 158:177-181, 1998
7. 7. Hayashi J, Kashiwagi S: Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment. Drugs Aging 11:296-308, 1997
8. 8. Yamaji K, Hayashi J, Kawakami Y, Furusyo N, Sawayama Y, Kishihara Y, Etoh Y, Kashiwagi S: Early clearance and reappearance of hepatitis C virus RNA in chronic hepatitis C patients treated with interferon-a. J Clin Gastroentel 26:193-199, 1998
9. 9. Ampurdanes S, Olmedo E, Maluenda MD, Forns X, Lopez-Labrador FX, Costa J, Sanchez-Tapias JM, de Anta MT, Rodes J: Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatol 25:827-832, 1996
10. 10. Karino Y, Toyota J, Sugawara M, Higashino K, Sato T, Ohmura T, Suga T, Okuuchi Y, Matsushima T: Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 92:61-65, 1996
11. 11. Sáez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, Carreno V: High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: A randomized, controlled trial. Hepatology 13:327-331, 1991
12. 12. Ohmiya M, Hayashi J, Furusyo N, Ueno K, Kishihara Y, Nabeshima S, Kashiwagi S: Large dose natural interferon alpha treatment for patients with chronic hepatitis C. Fukuoka Acta Med 88:380-388, 1997
13. 13. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, Wejstal R, Yun ZB, Weiland O: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology 19:280-285, 1994
14. 14. Hayashi J, Nakashima K, Kishihara Y, Ohmiya M, Yoshimura E, Hirata M, Kashiwagi S: Improved detection of antibodies to hepatitis C virus by the second-generation assay in patients with chronic non-A, non-B liver disease. J Infect 26:287-294, 1993
15. 15. Hayashi J, Yoshimura E, Kishihara Y, Yamaji K, Etoh Y, Ikematsu H, Kashiwagi S: Hepatitis C virus RNA levels determined by branched DNA probe assay correlated with levels assessed using competitive PCR. Am J Gastroenterol 91:314-318, 1996
16. 16. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi Y: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 73:673-679, 1992
17. 17. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS, Choo QL, Colombo M, Cuypers HTM, Date T, Dusheiko GM, Esteban JI, Fay O, Hadzyannis SJ, Han J, Hatzakis A, Holmes EC, Hotta H, Houghton M, Irwine B, Kohara M, Kolberg JA, Kuo G, Lau JYN, Lelie PN, Maertens G, McOmish F, Miyamura T, Mizokami M, Nomoto A, Prince AM, Reesink HW, Rice C, Roggendorf M, Schalm SW, Shikata T, Shimotohno K, Stuyver L, Trepo C, Weiner A, Yap PL, Urdea MS: A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321-1324, 1994
18. 18. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M: Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: Increase of the virus in advanced liver disease. Hepatology 18:16-20, 1993
19. 19. Snedecar GW, Cochran WG: Statistical Methods. Ames, Iowa, Iowa State University Press, 1980
20. 20. Hino K, Kondo T, Yasuda K, Fukuhara A, Fujioka S, Shimoda K, Niwa H, Iino S, Suzuki H: Pharmacokinetics and biological effects of beta interferon by intravenous (iv) bolus administration in healthy volunteers as compared with iv infusion. Jpn J Clin Pharmacol Ther 19:625-635, 1988
21. 21. Barouki FM, Witter FR, Griffin DE, Nadler PI, Woods A, Wood DL, Lietman PS: Time course of interferon levels, antiviral state, 2′,5′-oligoadenylate synthetase and side effects in healthy men. J Interferon Res 7:29-39, 1987
22. 22. Villa E, Trande P, Grottola A, Buttafoco P, Rebecchi AM, Stroffolini T, Callea F, Merighi A, Camellini L, Zoboli P, Cosenza R, Miglioli L, Loria P, Iori R, Carulli N, Manenti F: Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus: A prospective, double-blind, randomized study. Dig Dis Sci 41:1241-1247, 1996
23. 23. Pérez R, Pravia R, Artimez ML, Giganto F, Rodriguez M, Lombrana JL, Rodrigo L: Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis C. J Viral Hepatitis 2:103-106, 1995
24. 24. Saitoh H, Naitoh S, Okamoto H, Akahane Y: Prompt decrease of circulating hepatitis C virus in patients with chronic hepatitis C after treatment with interferon. J Interferon Res 14:239-244, 1994
25. 25. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL: Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172-3177, 1985
26. 26. Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Ohmiya M, Tani Y, Ikematsu H, Kashiwagi S: Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus. Dig Dis Sci 40:1837-1841, 1995
27. 27. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC: Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS 232:347-350, 1988
28. 28. Kakumu S, Fukatsu A, Shinagawa T, Kurokawa S, Kusakabe A: Localisation of intrahepatic interleukin 6 in patients with acute and chronic liver disease. J Clin Pathol 45:408-411, 1992
29. 29. Hashimoto H, Shibukawa N, Kojima Y: The mode of production of endotoxin-induced interferon in rabbit lymphoid cell cultures. II. Priming effect of interferon on apparently noninducible cells. Microbilo Immunol 23:1033-1036, 1979
30. 30. Satoh M, Shimada Y, Inagawa H, Minagawa H, Kajikawa T, Oshima H, Abe S, Yamazaki M, Mizuno D: Priming effect of interferons and interleukin 2 on endogenous production of tumor necrosis factor in mice. Jpn J Cancer Res 77:342-344, 1986
31. 31. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH: Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123:897-903, 1995
32. 32. Puoti C, Magrini A, Filippi T, Annovazzi G, Pannullo A: Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease. Eur J Gastroenterol Hepatol 7:151-154, 1995